IBM stock shows first recovery signs after holding $200
IBM is attempting to stabilize after a sharp selloff, while the planned acquisition of HRL strengthens its long-term quantum strategy. However, weak quarterly results and cautious fund positioning continue to limit buyer confidence.
The main corporate development was an agreement to acquire HRL Laboratories, a research company owned by Boeing and General Motors. HRL’s expertise in silicon spin qubits, quantum sensors and specialized materials should strengthen IBM’s quantum computing capabilities.
Financial terms were not disclosed, and the transaction is expected to close by the end of the third quarter of 2026. The acquisition cannot outweigh the weaker-than-expected quarterly report, but it does improve IBM’s long-term strategic position.

Buyers regain control near psychological support
The bearish scenario from the previous analysis played out: IBM shares failed to reclaim $212, broke below support at $204.30 and fell toward the psychological $200 level.The July 23 session closed with a green daily candle on relatively high volume, while buyers successfully defended $200. This provided the first indication of a possible recovery.
RSI (14) offers another positive signal. The indicator is in oversold territory, increasing the likelihood of a technical rebound.
The nearest target is resistance at $212. A decisive breakout and sustained move above this level could accelerate the recovery toward $220.
Rising Nasdaq shorts could cap IBM rebound
Early signs of stabilization are emerging against a backdrop of cautious positioning among professional market participants. According to the latest CFTC report, leveraged funds increased their short positions in Nasdaq-100 futures.This shift suggests that large market participants continue to hedge against a decline in the technology sector. As a result, even if the local rebound continues, IBM could face profit-taking near the $212 resistance level.